Roche reports a strong start in 2019 and raises the outlook for the full-year

In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Related Links:

Abstract PEGylation is a biochemical modification process of bioactive molecules with polyethylene glycol (PEG), which lends several desirable properties to proteins/peptides, antibodies, and vesicles considered to be used for therapy or genetic modification of cells. However, PEGylation of proteins is a complex process and can be carried out using more than one strategy that depends on the nature of the protein and the desired application. Proteins of interest are covalently conjugated or non-covalently complexed with inert PEG strings. Purification of PEGylated protein is another critical step, which is mainly c...
Source: Journal of Cell Communication and Signaling - Category: Molecular Biology Authors: Tags: J Cell Commun Signal Source Type: research
The development of neutralizing alloantibodies (inhibitors) to infused factor VIII (FVIII) remains the most significant complication of therapy in hemophilia A (HA). Despite some insights into genetic and environmental risk factors associated with inhibitor development, the immunological mechanisms behind this complication remain incompletely understood. Given that infused FVIII is likely encountered in the periphery, transitional B cell response to FVIII may regulate inhibitor development. Transitional B cell survival, maturation and proliferation are tightly regulated by the cytokine BLyS (B-lymphocyte stimulator). Eleva...
Source: Blood - Category: Hematology Authors: Tags: 321. Blood Coagulation and Fibrinolytic Factors: The Clotting System in Inflammation, Immunity, and Cancer Source Type: research
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.”
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
This article does not contain any studies with human participants or animals performed by the author. Data Availability All national (MagIran, Science Information Database (SID) and Iranmedex) and international (PubMed, Scopus) databases were searched from November 2010 to November 2016 using keywords both in English and Persian: Afghan immigrants, Afghan refugees, Iran, infectious diseases, tuberculosis, HIV, Hepatitis B and C, non-communicable disease, food security, mental health, barriers, health insurance, access to health service. All related websites and webpages were also searched by Google with the same keywords ...
Source: PLOS Currents Disasters - Category: International Medicine & Public Health Authors: Source Type: research
This article does not contain any studies with human participants or animals performed by the author. Data Availability All national (MagIran, Science Information Database (SID) and Iranmedex) and international (PubMed, Scopus) databases were searched from November 2010 to November 2016 using keywords both in English and Persian: Afghan immigrants, Afghan refugees, Iran, infectious diseases, tuberculosis, HIV, Hepatitis B and C, non-communicable disease, food security, mental health, barriers, health insurance, access to health service. All related websites and webpages were also searched by Google with the same keywords ...
Source: PLOS Currents Disasters - Category: International Medicine & Public Health Authors: Source Type: research
Today, 1989 may be most associated with Taylor Swift: It is the album that won her a second Grammy for Album of the Year. Not only that, it happens to be the year Swift was born--such a long, long time ago! People under 35 have no personal memory of 1980s pop culture, which is ironic since Swift's album in part pays homage to it. In the real 1989 (no offense to Swift and the 10 co-producers who made the album), all sorts of revolutions took place: Mr. Gorbachev tore down that pesky wall, for example. America's greatest antagonist, the Soviet Union, collapsed in 1989. Brazil conducted its first democrat...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
Abstract Therapeutic proteins are engineered proteins produced in the laboratory for pharmaceutical use. With the advent of recombinant DNA technology, the proteins can be generated in specific host cells under defined conditions. In the process of production of genetically engineered animals, the gene of interest can be added at a single cell stage to produce a cloned animal from genetically engineered cells. Several recombinant cytokines, clotting factors etc have been licensed and are currently being utilized for the treatment of cancer, infectious diseases, hemophilia, anemia, multiple sclerosis, and hepatitis...
Source: Current Protein and Peptide Science - Category: Biochemistry Authors: Tags: Curr Protein Pept Sci Source Type: research
In 2015, two issues related to medicine could be relied on to generate headlines: drug pricing and the proliferation of new value frameworks that claimed to define the value and even the price of drugs in seemingly easy-to-understand ways. In none of the high-profile skirmishes on pricing or frameworks was the voice or perspective of patients and patient groups very much in evidence. But that is beginning to change, in an evolution of a broader shift in the role that patients are playing in the research and development (R&D) enterprise. A New Culture of Engagement Patients and patient organizations are becoming ever more i...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: Costs and Spending Health Professionals Organization and Delivery Quality clinical research patient use of evidence venture philanthropy Source Type: blogs
So-called specialty drugs can represent lifesaving advances in the treatment of serious complex conditions, such as cancers, hepatitis C, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. They can turn once routinely lethal diseases such as HIV and cystic fibrosis into manageable chronic conditions. They can address rare genetic conditions, such as hemophilia, or suppress immune rejection after organ transplants.
Source: UCSF School of Pharmacy News - Category: Universities & Medical Training Authors: Source Type: news
Roche is today providing an update on its late-stage pipeline at an investor event in London, including promising investigational medicines for multiple sclerosis, asthma, haemophilia, eye disease and cancer. In these and other areas, Roche expects as many as seven major read-outs from clinical trials with new molecular entities or line extensions for existing medicines up to the end of 2017, adding to the seven read-outs already achieved in 2015.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Haemophilia | Hemophilia | Multiple Sclerosis | Pharmaceuticals